Skip to main content
SpringerLink
Log in

Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Hypertension frequently coexists with diabetes mellitus, occurring twice as frequently in diabetic as in nondiabetic persons. It accounts for up to 75% of added cardiovascular disease (CVD) risk in people with diabetes, contributing significantly to the overall morbidity and mortality in this high-risk population. Patients with hypertension are two times more prone to have diabetes than are normotensive persons. Hypertension substantially increases the risk for coronary heart disease (CHD), stroke, retinopathy, and nephropathy. In patients with type 2 diabetes, hypertension usually clusters with the other components of the cardiometabolic syndrome, such as microalbuminuria, central obesity, insulin resistance, dyslipidemia, hypercoagulation, increased inflammation, and left ventricular hypertrophy (LVH). In type 1 diabetes, hypertension often occurs subsequent to the development of diabetic nephropathy. Hypertension in people with diabetes is characterized by volume expansion, increased salt sensitivity, isolated systolic blood pressure (BP) elevation, loss of the nocturnal dipping of BP and pulse, and increased propensity toward orthostatic hypotension and albuminuria. Among the treatment strategies tested in hypertensive diabetic persons, low-density lipoprotein (LDL)-cholesterol lowering to less than 100 mg/ dL and aggressive BP control to less than 130/80 mm Hg have proven effective in CVD risk reduction. The combination of two or more drugs is usually necessary to achieve the target BP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Sowers JR, Haffner S: Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002, 40:781–788.

    Article  PubMed  CAS  Google Scholar 

  2. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.

    Article  PubMed  CAS  Google Scholar 

  3. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053–1059.

    PubMed  CAS  Google Scholar 

  4. Castro JP, El-Atat FA, McFarlane SI, et al.: Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep 2003, 5:393–401.

    PubMed  Google Scholar 

  5. Sowers JR, Lester MA: Diabetes and cardiovascular disease [review]. Diabetes Care 1999, 22(Suppl 3):C14-C20.

    PubMed  Google Scholar 

  6. Sowers JR, Bakris GL: Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000, 342:969–970.

    Article  PubMed  CAS  Google Scholar 

  7. Adler AI, Stratton IM, Neil HA, et al.: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412–419.

    Article  PubMed  CAS  Google Scholar 

  8. Sowers JR, Epstein M: Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension 1995, 26:869–879.

    PubMed  CAS  Google Scholar 

  9. Gress TW, Nieto J, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000, 342:905–912.

    Article  PubMed  CAS  Google Scholar 

  10. Kotchen TA, Zhang HY, Covelli M, Blehschmidt N:. Insulin resistance and blood pressure in Dahl rats and in one-kidney, oneclip hypertensive rats. Am J Physiol 1991, 261:E692-E697.

    PubMed  CAS  Google Scholar 

  11. Reaven GM, Chang H: Relationship between blood pressure, plasma insulin and triglyceride concentration, and insulin action in spontaneous hypertensive and Wistar-Kyoto rats. Am J Hypertens 1991, 4:34–38.

    PubMed  CAS  Google Scholar 

  12. Sechi LA, Melis A, Tedde R: Insulin hypersecretion: a distinctive feature between essential and secondary hypertension. Metabolism 1992, 41:1261–1266.

    Article  PubMed  CAS  Google Scholar 

  13. Beatty OL, Harper R, Sheridan B, et al.: Insulin resistance in offspring of hypertensive parents. BMJ 1993, 307:92–96.

    PubMed  CAS  Google Scholar 

  14. Grunfeld B, Balzareti M, Romo M, et al.: Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994, 23:I12-I15.

    PubMed  CAS  Google Scholar 

  15. Sowers JR: Insulin resistance and hypertension. Am J Phys, In press.

  16. Walsh MF, Barazi M, Sowers JR: IGF-1 diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996, 137:1798–1803.

    Article  PubMed  CAS  Google Scholar 

  17. Sowers JR: Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997, 29:691–699. In this paper, the current understanding of mechanisms of the hemodynamic, metabolic, and growth effects of insulin and IGF-1 exerted on CV tissue is reviewed. The paper provides a clear, scientific explanation of these effects in hyperinsulinemia and the insulin-resistant state. Furthermore, it gains major importance status with discussion of both normal and pathologic aspects of insulin and IGF-1 actions.

    PubMed  CAS  Google Scholar 

  18. Isenovic ER, Divald A, Milivojevic N, et al.: Interactive effects of insulin-like growth factor-1 and estradiol on endothelial nitric oxide synthase activity in rat aortic endothelial cells. Metabolism 2003, 52:482–487.

    Article  PubMed  CAS  Google Scholar 

  19. Walsh MF, Ali S, Sowers JR: Vascular insulin/insulin-like growth factor-1 resistance in female obese Zucker rats. Metabolism 2001, 50:607–612.

    Article  PubMed  CAS  Google Scholar 

  20. Williams B: Insulin resistance: the shape of things to come. Lancet 1994, 344:521–524.

    Article  PubMed  CAS  Google Scholar 

  21. Nickenig G, Roling J, Strehlow K, et al.: Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998, 98:2453–2460.

    PubMed  CAS  Google Scholar 

  22. Dengel DR, Hagberg JM, Pratley RE, et al.: Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men. Metabolism 1998, 47:1075–1082. The effect of modifying insulin resistance on BP control is evaluated. A beneficial effect of aerobic exercise training (AET) in improving insulin sensitivity and lowering BP among sedentary, nondiabetic, hypertensive subjects is demonstrated.

    Article  PubMed  CAS  Google Scholar 

  23. Ogihara T, Rakugi H, Ikegami H, et al.: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995, 8:316–320.

    Article  PubMed  CAS  Google Scholar 

  24. Raji A, Seely EW, Bekins SA, et al.: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003, 26:172–178.

    Article  PubMed  CAS  Google Scholar 

  25. El-Atat F, Aneja A, Mcfarlane SI, Sowers JR: Obesity, hypertension and other cardiovascular sequelae. Endocrinol Metab Clin North Am 2003, In press. This paper is a very thorough review of the maladaptive CV and metabolic responses to obesity in the cardiometabolic syndrome, with a focus on obesity-related hypertension, including the pathophysiology and treatment of this entity.

  26. Garrison RJ, Kannel WB, Stokes J, Castelli WP: Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987, 16:234–251.

    Article  Google Scholar 

  27. Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesityassociated cardiovascular and renal disease. Am J Med Sci 2002, 324:127–137.

    Article  PubMed  Google Scholar 

  28. Zhang R, Reisin E: Obesity-hypertension: the effects on cardiovascular and renal systems. Am J Hypertens 2000, 13:1308–1314.

    Article  PubMed  CAS  Google Scholar 

  29. Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001, 14:103S-115S.

    Article  PubMed  CAS  Google Scholar 

  30. Melo LG, Veress AT, Chong CK, et al.: Salt-sensitive hypertension in ANP knockout mice: potential role of abnormal plasma-renin activity. Am J Physiol 1998, 274:R255-R261.

    PubMed  CAS  Google Scholar 

  31. Semplicini A, Ceolotto G, Massimino M, et al.: Interactions between insulin and sodium homeostasis in essential hypertension. Am J Med Sci 1994, 307(Suppl 1):S43-S46.

    PubMed  Google Scholar 

  32. Weinberger MH: Salt sensitive human hypertension. Endocr Res 1991, 17:43–51.

    PubMed  CAS  Google Scholar 

  33. Luft FC, Miller JZ, Grim CE, et al.: Salt sensitivity and resistance of blood pressure: age and race as factors in physiological responses. Hypertension 1991, 17:I102-I108.

    PubMed  CAS  Google Scholar 

  34. Weinberger MH, Fineberg NS: Sodium and volume sensitivity of blood pressure: age and pressure change over time. Hypertension 1991, 18:67–71.

    PubMed  CAS  Google Scholar 

  35. Verdecchia P, Porcellati C, Schillaci G, et al.: Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994, 24:793–801.

    PubMed  CAS  Google Scholar 

  36. Nakano S, Kitazawa M, Tsuda S, et al.: Insulin resistance is associated with reduced nocturnal falls of blood pressure in normotensive, nonobese type 2 diabetic subjects. Clin Exp Hypertens 2002, 24:65–73.

    Article  PubMed  Google Scholar 

  37. Nielsen FS, Hansen HP, Jacobsen P, et al.: Increased sympathetic activity during sleep and nocturnal hypertension in type 2 diabetic patients with diabetic nephropathy. Diabet Med 1999, 16:555–562.

    Article  PubMed  CAS  Google Scholar 

  38. Ohkubo T, Hozawa A, Yamaguchi J, et al.: Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 2002, 20:2183–2189.

    Article  PubMed  CAS  Google Scholar 

  39. White WB: A chronotherapeutic approach to the management of hypertension. Am J Hypertens 1996, 9:29S-33S.

    PubMed  CAS  Google Scholar 

  40. Arun CS, Stoddart J, Mackin P, et al.: Significance of microalbuminuria in long-duration type 1 diabetes. Diabetes Care 2003, 26:2144–2149.

    Article  PubMed  Google Scholar 

  41. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718. This paper is of particular importance in the molecular aspect of the cardiometabolic syndrome and insulin-resistant state. In addition to being written by pioneers in the area of cardiometabolic syndrome, hyperinsulinemia, and insulin resistance, it carries a wealth of informative illustrations and detailed descriptions of the molecular mechanisms that underlie the insulin-resistant state.

    Article  PubMed  CAS  Google Scholar 

  42. Mitchell TH, Nolan B, Henry M, et al.: Microalbuminuria in patients with non-insulin-dependent diabetes mellitus relates to nocturnal systolic blood pressure. Am J Med 1997, 102:531–535.

    Article  PubMed  CAS  Google Scholar 

  43. Mogensen CE: Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003, 254:45–66.

    Article  PubMed  CAS  Google Scholar 

  44. Tagle R, Acevedo M, Vidt DG: Microalbuminuria: Is it a valid predictor of cardiovascular risk? Cleve Clin J Med 2003, 70:255–261.

    Article  PubMed  Google Scholar 

  45. McFarlane SI, Farag A, Sowers J: Calcium antagonists in patients with type 2 diabetes and hypertension. Cardiovasc Drug Rev 2003, 21:105–118.

    Article  PubMed  CAS  Google Scholar 

  46. Streeten DH, Anderson GH Jr: The role of delayed orthostatic hypotension in the pathogenesis of chronic fatigue. Clin Auton Res 1998, 8:119–124.

    Article  PubMed  CAS  Google Scholar 

  47. Streeten DH, Auchincloss JH Jr, Anderson GH Jr, et al.: Orthostatic hypertension: pathogenetic studies. Hypertension 1985, 7:196–203.

    PubMed  CAS  Google Scholar 

  48. Jacob G, Costa F, Biaggioni I: Spectrum of autonomic cardiovascular neuropathy in diabetes. Diabetes Care 2003, 26:2174–2180.

    Article  PubMed  Google Scholar 

  49. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  50. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703–713.

    Google Scholar 

  51. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  52. Arauz-Pacheco C, Parrott MA, Raskin P: Treatment of hypertension in adults with diabetes. Diabetes Care 2003, 26(Suppl 1):S80-S82.

    PubMed  Google Scholar 

  53. Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646–661.

    PubMed  CAS  Google Scholar 

  54. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.

    Article  Google Scholar 

  55. Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASHSodium Collaborative Research Group. N Engl J Med 2001, 344:3–10.

    Article  PubMed  CAS  Google Scholar 

  56. Appel LJ, Moore TJ, Obarzanek E, et al.: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997, 336:1117–1124.

    Article  PubMed  CAS  Google Scholar 

  57. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  58. Bakris GL, Sowers JR: Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. Curr Diab Rep 2002, 2:258–262.

    Article  PubMed  Google Scholar 

  59. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.

    Article  Google Scholar 

  60. McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H-37H.

    Article  PubMed  CAS  Google Scholar 

  61. McFarlane SI, Shin JJ, Rundek T, Bigger JT: Prevention of type 2 diabetes. Curr Diab Rep 2003, 3:235–241.

    Article  PubMed  Google Scholar 

  62. Shindler DM, Kostis JB, Yusuf S, et al.: Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996, 77:1017–1020.

    Article  PubMed  CAS  Google Scholar 

  63. Rake EC, Breeze E, Fletcher AE: Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo. J Hum Hypertens 2001, 15:863–867.

    Article  PubMed  CAS  Google Scholar 

  64. Kendall MJ: Therapeutic advantages of AT1 blockers in hypertension. Basic Res Cardiol 1998, 93(Suppl 2):47–50.

    Article  PubMed  CAS  Google Scholar 

  65. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  66. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.

    Article  PubMed  CAS  Google Scholar 

  67. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.

    Article  PubMed  CAS  Google Scholar 

  68. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713–720.

    Google Scholar 

  69. McFarlane SI, Jacober SJ, Winer N, et al.: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718–723.

    Article  PubMed  Google Scholar 

  70. Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4:393–405.

    Google Scholar 

  71. Black HR, Elliott WJ, Neaton JD, et al.: Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension 2001, 37:12–18.

    PubMed  CAS  Google Scholar 

  72. Birkenhager WH, Staessen JA, Gasowski J, de Leeuw PW: Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial. J Nephrol 2000, 13:232–237.

    PubMed  CAS  Google Scholar 

  73. Mallion JM, Benkritly A, Hansson L, Zanchetti A: [Effect of intensive antihypertensive treatment and of aspirin in a low dose in the hypertensive. The HOT (Hypertension Optimal Treatment) study]. Arch Mal Coeur Vaiss 1999, 92:1073–1078.

    PubMed  CAS  Google Scholar 

  74. Barzilay JI, Jones CL, Davis BR, et al.: Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2001, 24:654–658.

    Article  PubMed  CAS  Google Scholar 

  75. Bakris GL, Weir MR: Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 2003, 5:202–209.

    Article  CAS  Google Scholar 

  76. Law MR, Wald NJ, Morris JK, Jordan RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326:1427.

    Article  PubMed  CAS  Google Scholar 

  77. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Missouri-Columbia, MA410 Health Science Center, One Hospital Drive, 65212, Columbia, MO, USA

    Fadi El-Atat MD, Samy I. McFarlane MD & James R. Sowers MD

Authors
  1. Fadi El-Atat MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samy I. McFarlane MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James R. Sowers MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Atat, F., McFarlane, S.I. & Sowers, J.R. Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management. Current Science Inc 6, 215–223 (2004). https://doi.org/10.1007/s11906-004-0072-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-004-0072-y

Keywords

Search

Navigation